Reprogramming endocytic trafficking of antibody-drug conjugates to enhance tumor penetration and lysosomal delivery.
Antibody-drug conjugates (ADCs) have transformed cancer treatment; however, challenges such as heterogeneous antigen expression and inefficient intracellular delivery continue to limit their clinical efficacy. Herein, we present a novel "signal-fusion" ADC strategy in which trafficking signal peptides were genetically...